Merkel Cell Carcinoma Pipeline Insight, 2020

Merkel Cell Carcinoma Pipeline Insight, 2020

DelveInsight has launched a new report on Merkel Cell Carcinoma Pipeline Insight, 2020

“Merkel Cell Carcinoma Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Merkel Cell Carcinoma market. A detailed picture of the Merkel Cell Carcinoma pipeline landscape is provided, which includes the disease overview and Merkel Cell Carcinoma treatment guidelines. The assessment part of the report embraces in-depth Merkel Cell Carcinoma commercial assessment and clinical assessment of the Merkel Cell Carcinoma pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Merkel Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The Merkel Cell Carcinoma market report provides current treatment practices, emerging drugs, Merkel Cell Carcinoma market share of the individual therapies, current and forecasted Merkel Cell Carcinoma market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Merkel Cell Carcinoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Merkel Cell Carcinoma (MCC) is a rare, highly aggressive neuroendocrine cutaneous neoplasm with a variable clinical presentation. It is a predominantly dermal-based lesion composed of monotonous small round cells with scanty cytoplasm, often difficult to differentiate from small round cell tumors, metastatic small cell carcinoma, blastic hematologic malignancies, and melanoma.
Request for:- free sample page
Merkel Cell Carcinoma of pipeline development activities 

The report provides insights into: 

  • All of the companies that are developing therapies for the treatment of Merkel Cell Carcinoma with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Merkel Cell Carcinoma treatment.
  • Merkel Cell Carcinoma key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Merkel Cell Carcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.  


Merkel Cell Carcinoma Analytical Perspective by DelveInsight

  • In-depth Merkel Cell Carcinoma Commercial Assessment of products 

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

  • Merkel Cell Carcinoma Clinical Assessment of products 

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

 Scope of the report

  • The Merkel Cell Carcinoma report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Merkel Cell Carcinoma across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Merkel Cell Carcinoma therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Merkel Cell Carcinoma research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Merkel Cell Carcinoma.

Key major companies are working on MCC that are given below:- 

1. Merck Pharma Co.
2. Incvte Corporation
3. Kartos Therapeutics
Name of covered drugs that are given below:-

1. Avelumab
2. Pembrolizumab
3. INCMGA00012

Table of contents

1. Report Introduction

2. Merkel Cell Carcinoma 

2.1. Overview

2.2. History 

2.3. Merkel Cell Carcinoma Symptoms

2.4. Causes


2.6. Merkel Cell Carcinoma Diagnosis 

2.6.1. Diagnostic Guidelines

3. Merkel Cell Carcinoma Current Treatment Patterns

3.1. Merkel Cell Carcinoma Treatment Guidelines

4. Merkel Cell Carcinoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Merkel Cell Carcinoma Late Stage Products (Phase-III)

7. Merkel Cell Carcinoma Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Merkel Cell Carcinoma Discontinued Products

13. Merkel Cell Carcinoma Product Profiles

14. Merkel Cell Carcinoma Key Companies

15. Merkel Cell Carcinoma Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Merkel Cell Carcinoma Unmet Needs

18. Merkel Cell Carcinoma Future Perspectives

19. Merkel Cell Carcinoma Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation 

22. About Delveinsight

Related Reports

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States